Skip to main content

Table 3 Adverse events observed in patients administered adjuvant chemotherapy with S-1

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

Toxicity

No. of patients (%)

Grade 3 or higher

All

Hematological toxicity

 Neutropenia

1

(3.3)

9

(30.0)

 Leukopenia

1

(3.3)

8

(26.7)

 Anemia

0

(0.0)

5

(16.7)

 Thrombocytopenia

0

0.0

3

(10.0)

 Febrile neutropenia

0

(0.0)

1

(3.3)

Non-hematological toxicity

 Nausea

1

(3.3)

8

(26.7)

 Diarrhea

1

(3.3)

4

(13.3)

 Anorexia

1

(3.3)

12

(40.0)

 Fatigue

0

(0.0)

11

(36.7)

 Stomatitis

0

0.0

4

(13.3)

 Abdominal distension

0

0.0

1

(3.3)

 Alopecia

0

0.0

1

(3.3)

 Dry skin

0

0.0

3

(6.7)

 Dysgeusia

0

0.0

4

(13.3)

 Skin pigmentation

0

0.0

6

(20.0)